https://scholars.lib.ntu.edu.tw/handle/123456789/193249
標題: | Application of Rituximab to Hepatitis C-Positive, Abo-Incompatible Renal Transplantation | 作者: | TSAI, MENG-KUN 李伯皇 |
關鍵字: | Hepatitis C virus;Rituximab;ABO-incompatible renal transplantation | 公開日期: | 2009 | 卷: | v.32 | 期: | n.5 | 起(迄)頁: | 308-309 | 來源出版物: | INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS | 摘要: | A safety issue has been noted in applying rituximab to renal transplant patients with HCV infection, as a hepatitis C virus (HCV) flare-up and lethal cholestatic hepatitis C occurred in a renal transplant patient treated with rituximab for lymphoproliferative disorder. As double- filtration plasmapheresis (DFPP) and cyclosporine were reported to reduce hepatitis C viremia, we performed ABO- incompatible renal transplantation in two patients with positive HCV RNA by using rituximab, DFPP and cyclosporine- based immunosuppressant. The HCV RNA level was 3.3 x 10(5) IU/mL for Case 1 and 1.2 x 10(3) IU/mL for Case 2 before DFPP. After DFPP and renal transplantation, Case 1 had stable ALT levels and a transient decrease in HCV RNA to 7.9 x 10(4) IU/mL at 1 month followed by a gradual increase to 7.6 x 10(6) at 12 months, but Case 2 had a dramatic and persistent elevation of HCV RNA to 7.7 x 10(6) from 1 week to 12 months accompanied by elevated ALT levels. The serum creatinine levels were 1.5 mg/dL for Case 1 and 1.9 mg/dL for Case 2 at 12 months. Although cholestatic hepatitis C did not occur in our patients, who received rituximab for ABO-incompatible renal transplantation, the antiviral effect of cyclosporine and DFPP did not seem evident. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/185885 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。